# Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke

Study · id `cardio:ct-nct04962451` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04962451](<https://clinicaltrials.gov/study/NCT04962451>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04962451

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 13000 participants.

## Technical summary

Registry record NCT04962451. Randomized; double masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2019-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 13000 participants (enrolled count; ClinicalTrials.gov record NCT04962451, source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)
- Started: 2017-09-01 (actual) (ClinicalTrials.gov record NCT04962451, source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)
- Primary completion: 2019-09-30 (actual) (ClinicalTrials.gov record NCT04962451, source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)
- Completion: 2019-10-31 (actual) (ClinicalTrials.gov record NCT04962451, source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04962451, source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04962451-2021-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
- Condition: Cerebrovascular Accident
- Condition: Cerebrovascular Accident, Acute
- Intervention (Drug): ticagrelor + ASA
- Intervention (Drug): Placebo+ASA
- Lead sponsor: Peking University Third Hospital
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Peking University Third Hospital (`cardio:org-peking-university-third-hospital`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 51a22ea67b74f22cd2715192357731f6a04688a6e86603a63b99c1762dc1e5b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
